Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MDS by bone marrow biopsy based on the World Health Organization (WHO) classification~* Low or Intermediate-1 risk category MDS using the IPSS~* Planned to receive lenalidomide 10 mg capsule by mouth daily for all 28 days of each cycle for at least 4 cycles~* Eastern Cooperative Oncology (ECOG) performance status of 0-2~* Subjects must be at least 18 years of age or older~Exclusion Criteria:~* Prior exposure to \>3 cycles of lenalidomide~* Exposure to lenalidomide within the last 30 days~* Prior history of leukemia or aplastic anemia~* Prior history of stem cell transplantation~* Prior malignancy (other than in situ cervical cancer or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for 3 years before randomization~* Active or uncontrolled infections~* Unstable angina, congestive heart failure \[NYHA \> class II\], uncontrolled hypertension \[diastolic \> 100 mmHg\], uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction~* History of arterial thrombosis ( eg, stroke or transient ischemic attack) in the past year~* History of venous thrombosis in the past year~* Received IL-11 within 4 weeks of screening~* Less than 4 weeks since receipt of any investigational drug or device~* Have previously received any other thrombopoietic growth factor~* Pregnant or breast feeding~* Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator~* Known hypersensitivity to any recombinant E coli-derived product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 750 mcg AMG 531 (Type: ACTIVE_COMPARATOR): 750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
- Placebo Part B (Type: PLACEBO_COMPARATOR): Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
- Placebo Part A (Type: PLACEBO_COMPARATOR): Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
- 500 mcg AMG 531 (Type: ACTIVE_COMPARATOR): 500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
- 750 mcg AMG531 Part B (Type: ACTIVE_COMPARATOR): 750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)

Based on this trial design, predict the completion outcome and termination type (if applicable).